Demonstrating better tolerability and safety in comparison with standard of care, Edgewise Therapeutics Inc.’s EDG-7500 is moving toward a phase III trial for both...

Harnessing an oncolytic signal and redirecting it against the tumor itself could be developed as a selective strategy for certain cancer types, as occurs with ErbB...

Stay up to date as BioWorld reports on the latest developments of the Ebola virus public health emergency.

China’s National Medical Products Administration has approved Suzhou Alphamab Co. Ltd.’s HER2 bispecific antibody, anbenitamab (KN-026), through priority review for adults...